Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Laboratory Corporation of America Holdings / Equity Bottom-Up

Laboratory Corporation of America Holdings

<ul><li>Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although not without its challenges.</li><li>The company reported a revenue increase of 7% year-over-year to $3.3 billion, with Diagnostics Laboratories exhibiting a 9% growth while Biopharma Laboratory Services rose by approximately 3%.</li><li>Despite these growth figures, the company faced margin pressures, partially due to the integration of Invitae, resulting in a 40-basis point decrease in enterprise margins.</li></ul>

Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although not without its challenges.The company reported a revenue increase of 7% year-over-year to $3.3 billion, with Diagnostics Laboratories exhibiting a 9% growth while Biopharma Laboratory Services rose by approximately 3%.Despite these growth figures, the company faced margin pressures, partially due to the integration of Invitae, resulting in a 40-basis point decrease in enterprise margins.

Laboratory Corporation of America Holdings (LabCorp):  Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts

<ul><li>Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business operations.</li><li>The company reported impressive figures with revenues totaling $3.2 billion, reflecting a 6% increase compared to the same period in 2023.</li><li>Adjusted earnings per share (EPS) also saw an appreciable rise, reaching $3.94, signifying a 15% increase.</li></ul>

Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business operations.The company reported impressive figures with revenues totaling $3.2 billion, reflecting a 6% increase compared to the same period in 2023.Adjusted earnings per share (EPS) also saw an appreciable rise, reaching $3.94, signifying a 15% increase.

Laboratory Corporation of America Holdings (LabCorp): Expansion into Hospital & Regional Laboratory Markets & Focus on High-Growth Specialty Testing Markets! - Major Drivers

<ul><li>Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.</li><li>The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.</li><li>Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.</li></ul>

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

<ul><li>Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth.</li><li>Discussing Q4 results, revenues reached $3 billion, adjusted earnings per share was $3.30, and free cash flow from operations, excluding spin-related items, was $422 million.</li><li>Enterprise revenue grew by 4% compared to Q4 2022, led by an 8% growth in the Diagnostics business and 7% growth in the Biopharma business.</li></ul>

Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth.Discussing Q4 results, revenues reached $3 billion, adjusted earnings per share was $3.30, and free cash flow from operations, excluding spin-related items, was $422 million.Enterprise revenue grew by 4% compared to Q4 2022, led by an 8% growth in the Diagnostics business and 7% growth in the Biopharma business.

Laboratory Corporation of America (LabCorp): Significant Growth Momentum In The Diagnostics & Women's Health Can Revolutionize Growth? - Major Drivers

<ul><li>Laboratory Corporation of America delivered a disappointing set of results as the company was unable to meet the revenue expectations as well as the earnings expectations of Wall Street.</li><li>Base business revenue and base business revenue of Diagnostic Laboratories grew driven by strong base business volume and Ascension.</li><li>Labcorp, a segment of the company's laboratory services business, delivered exceptional growth in its Diagnostic Laboratories and generated strong progress in Central Laboratories.</li></ul>

Laboratory Corporation of America delivered a disappointing set of results as the company was unable to meet the revenue expectations as well as the earnings expectations of Wall Street.Base business revenue and base business revenue of Diagnostic Laboratories grew driven by strong base business volume and Ascension.Labcorp, a segment of the company's laboratory services business, delivered exceptional growth in its Diagnostic Laboratories and generated strong progress in Central Laboratories.

Laboratory Corporation of America Holdings: Does It Have A Sustainable Competitive Advantage? - Key Drivers

United States

Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. The Company develops specialty testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.

Laboratory Corporation of America Holdings (LH US)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America Holdings (LabCorp): Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts

Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although...

Baptista Research

Laboratory Corporation of America Holdings (LabCorp): Expansion into Hospital & Regional Laboratory Markets & Focus on High-Growth Specialty Testing Markets! - Major Drivers

Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business...

Baptista Research

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for...

Baptista Research

Laboratory Corporation of America (LabCorp): Significant Growth Momentum In The Diagnostics & Women's Health Can Revolutionize Growth? - Major Drivers

Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth. Discussing Q4...

Baptista Research

Laboratory Corporation of America Holdings: Does It Have A Sustainable Competitive Advantage? - Key Drivers

Laboratory Corporation of America delivered a disappointing set of results as the company was unable to meet the revenue expectations as well as...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)